Rapid Minimal Residual Disease Clearance with More Stringent Age-Related Dose Criteria Improves Prognosis in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia

被引：0
|
作者：
Ishihara, T. [1 ]
Arakawa, Y. [2 ]
Miyamura, T. [3 ]
Nogami, Y. [4 ]
Ishimaru, S. [4 ,5 ]
Takachi, T. [6 ]
Yano, M. [7 ]
Sasaki, S. [8 ]
Saito, A. [9 ]
Deguchi, T. [10 ]
Hori, T. [11 ]
Yamada, T. [9 ]
Sanada, M. [9 ]
Manabe, A. [12 ]
Horibe, K.
Imamura, T. [13 ]
Tomizawa, D. [10 ]
机构：
[1] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan
[2] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan
[3] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka, Japan
[4] Natl Canc Ctr, Dept Pediat Oncol, Tokyo, Japan
[5] Princess Maxima Ctr Pediat Oncol, Trial & Data Ctr, Utrecht, Netherlands
[6] Shizuoka Childrens Hosp, Dept Hematol & Oncol, Shizuoka, Japan
[7] Kyoto City Hosp, Dept Pediat, Kyoto, Japan
[8] Hirosaki Univ, Grad Sch Med, Dept Pediat, Hirosaki, Aomori, Japan
[9] Natl Hosp Org, Nagoya Med Ctr, Clin Res Ctr, Nagoya, Aichi, Japan
[10] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan
[11] Aichi Med Univ, Dept Pediat, Nagakute, Aichi, Japan
[12] Hokkaido Univ, Dept Pediat, Sapporo, Hokkaido, Japan
[13] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O0178
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 37 条
  • [31] Concordance and Prognostic Significance of Minimal Residual Disease Detection in Peripheral Blood and Bone Marrow Samples of Infants with MLL-rearranged Acute Lymphoblastic Leukemia Treated By MLL-Baby Protocol
    Tsaur, Grigory
    Popov, Alexander
    Riger, Tatyana
    Solodovnikov, Alexander
    Nasedkina, Tatyana
    Kustanovich, Anatoly
    Tsvirenko, Sergey
    Streneva, Olga
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    BLOOD, 2014, 124 (21)
  • [32] PROGNOSTIC SIGNIFICANCE OF THE MINIMAL RESIDUAL DISEASE EVALUATED BY DETECTION OF MLL FUSION GENE TRANSCRIPTS IN INFANTS UNDER 1 YEAR OF AGE WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED BY THE MLL-BABY PROTOCOL
    Tsaur, G. A.
    Popov, A. M.
    Nasedkina, T. V.
    Kalennik, O. V.
    Kustanovich, A. M.
    Aleinikova, O. V.
    Solodovnikov, A. G.
    Riger, T. O.
    Streneva, O. V.
    Shorikov, E. V.
    Savelyev, L. I.
    Fechina, L. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2012, 57 (04): : 12 - 22
  • [33] Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis
    Herold, Tobias
    Schneider, Stephanie
    Metzeler, Klaus H.
    Neumann, Martin
    Hartmann, Luise
    Roberts, Kathryn G.
    Konstandin, Nikola P.
    Greif, Philipp A.
    Braeundl, Kathrin
    Ksienzyk, Bianka
    Huk, Natalia
    Schneider, Irene
    Zellmeier, Evelyn
    Jurinovic, Vindi
    Mansmann, Ulrich
    Hiddemann, Wolfgang
    Mullighan, Charles G.
    Bohlander, Stefan K.
    Spiekermann, Karsten
    Hoelzer, Dieter
    Bruggemann, Monika
    Baldus, Claudia D.
    Dreyling, Martin
    Goekbuget, Nicola
    HAEMATOLOGICA, 2017, 102 (01) : 130 - 138
  • [34] Impact of minimal residual disease (MRD) on prognosis in children with acute lymphoblastic leukemia (ALL) according to WBC count, age and TEL/AML1 status at diagnosis. results of the AIEOP-BFM ALL 2000 study.
    Conter, Valentino
    Schrauder, Andre
    Gadner, Helmut
    Valsecchi, Maria Grazia
    Zimmermann, Martin
    Dvorzak, Michael
    Biondi, Andrea
    Bartram, Claus R.
    Basso, Giuseppe
    Stanulla, Martin
    Arico, Maurizio
    Welte, Karl
    Masera, Giuseppe
    Schrappe, Martin
    BLOOD, 2007, 110 (11) : 167A - 167A
  • [35] A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
    Tasian, Sarah K.
    Hunter, Deborah S.
    Chen, I-Ming L.
    Harvey, Richard C.
    Carroll, Andrew J.
    Wagner, Elizabeth
    Reshmi, Shalini C.
    Borowitz, Michael J.
    Wood, Brent L.
    Daniel, Jeannie
    Devidas, Meenakshi
    Raetz, Elizabeth A.
    Hunger, Stephen P.
    Assad, Albert
    Loh, Mignon L.
    BLOOD, 2022, 140 : 6117 - 6118
  • [36] The Prognosis of Children Acute Lymphoblastic Leukemia (ALL) with Minimal Residual Disease (MRD) ≥10-2 After Induction (TP1) Depends on the Prephase Response and on the Level of the MRD After Consolidation (TP2): Results of the 58951EORTC Trial
    Bertrand, Yves
    Suciu, Stefan
    Grardel, Nathalie
    Bakkus, Marleen
    Mazingue, Francoise
    Yacouben, Karima
    Uyttebroeck, Anne
    Lutz, Patrick
    Plantaz, Dominique
    Girard, Sandrine
    Dastugue, Nicole
    Benoit, Yves
    Cave, Helene
    BLOOD, 2011, 118 (21) : 1103 - 1103
  • [37] Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Adult Patients with t(4;11)(q21;q23) KMT2A/AFF1 (MLL/AF4) B-Acute Lymphoblastic Leukemia in First Complete Remission (CR1): Favorable Outcome of Patients with Negative Minimal Residual Disease (MRD) Status at Transplant. a Report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT)
    Esteve, Jordi
    Labopin, Myriam
    Czerw, Tomasz
    Wu, Depei
    Volin, Liisa
    Socie, Gerard
    Jouet, Jean-Pierre
    Maertens, Johan
    Cornelissen, Jan J.
    Pigneux, Arnaud
    Shimoni, Avichai
    Schwerdtfeger, Rainer
    Michallet, Mauricette
    Russell, Nigel H.
    Chevallier, Patrice
    Schattenberg, Antonius V. M. B.
    Koza, Vladimir
    Foa, Robin
    Schmid, Christoph
    Giebel, Sebastian
    Mohty, Mohamad
    Nagler, Arnon
    BLOOD, 2017, 130
1234